newsfilter
← Latest News
GlobeNewswire·

NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers

First IND for NexImmune's AIM nanoparticle platform in solid tumors IND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), in patients with relapsed or refractory human pa